Oxidative stress and immune thrombocytopenia

Seminars in Hematology

Volumn 50, Issue 3, 2013, Pages e1-

  Zhang, Bing ^a   Zehnder, James L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE; GLUTAMATE DECARBOXYLASE 65; GLUTATHIONE PEROXIDASE; HUMAN SERUM ALBUMIN; LIPID HYDROPEROXIDE; NITRIC OXIDE; PEROXIREDOXIN; POLYUNSATURATED FATTY ACID; REACTIVE OXYGEN METABOLITE;

ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; DISEASE ASSOCIATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID PEROXIDATION; LYMPHOCYTE FUNCTION; NITRATION; NITROSATIVE STRESS; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNITY; HUMANS; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; THROMBOCYTOPENIA;

EID: 84881595629     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.06.011     Document Type: Article

References (32)

1. Lee I.T., Yang C.M. Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases. Biochem Pharmacol 2012, 84(5):581-590.
2. Malhotra J.D., Kaufman R.J. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword?. Antioxid Redox Signal 2007, 9(12):2277-2293.
3. Grimsrud P.A., Xie H., Griffin T.J., et al. Oxidative stress and covalent modification of protein with bioactive aldehydes. J Biol Chem 2008, 283(32):21837-21841.
4. Dalle-Donne I., Rossi R., Colombo R., et al. Biomarkers of oxidative damage in human disease. Clin Chem 2006, 52(4):601-623.
5. Kurien B.T., Scofield R.H. Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 2008, 7(7):567-573.
6. Kurien B.T., Hensley K., Bachmann M., et al. Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med 2006, 41(4):549-556.
7. Sheikh Z., Ahmad R., Sheikh N., et al. Enhanced recognition of reactive oxygen species damaged human serum albumin by circulating systemic lupus erythematosus autoantibodies. Autoimmunity 2007, 40(7):512-520.
8. Ben Mansour R., Lassoued S., Elgaied A., et al. Enhanced reactivity to malondialdehyde-modified proteins by systemic lupus erythematosus autoantibodies. Scand J Rheumatol 2010, 39(3):247-253.
9. Wang G., Pierangeli S.S., Papalardo E., et al. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum 2010, 62(7):2064-2072.
10. +/+ mice treated with trichloroethene and dichloroacetyl chloride: possible role of lipid peroxidation in autoimmunity. Toxicol Appl Pharmacol 2001, 170(2):88-92.
11. +/+ mice exposed to trichloroethene: potential role of protein oxidation in autoimmunity. Toxicol Appl Pharmacol 2009, 237(2):188-195.
12. Scofield R.H., Kurien B.T., Ganick S., et al. Modification of lupus-associated 60-kDa Ro protein with the lipid oxidation product 4-hydroxy-2-nonenal increases antigenicity and facilitates epitope spreading. Free Radic Biol Med 2005, 38(6):719-728.
13. Griffiths H.R. Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease?. Autoimmun Rev 2008, 7(7):544-549.
14. Rasheed Z., Ali R. Reactive oxygen species damaged human serum albumin in patients with type 1 diabetes mellitus: biochemical and immunological studies. Life Sci 2006, 79(24):2320-2328.
15. Khan M.W., Sherwani S., Khan W.A., et al. Characterization of hydroxyl radical modified GAD65: a potential autoantigen in type 1 diabetes. Autoimmunity 2009, 42(2):150-158.
16. Delmastro MM, Piganelli JD. Oxidative stress and redox modulation potential in type 1 diabetes. Clin Dev Immunol. 2011:593863. Epub 2011 May 18.
17. Zhang B., Lo C., Shen L., et al. The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP. Blood 2011, 117(17):4569-4579.
18. Akbayram S., Doǧan M., Akgün C., et al. The association of oxidant status and antioxidant capacity in children with acute and chronic ITP. J Pediatr Hematol Oncol 2010, 32(4):277-281.
19. Polat G., Tamer L., Tanriverdi K., et al. Levels of malondialdehyde, glutathione and ascorbic acid in idiopathic thrombocytopaenic purpura. East Afr Med J 2002, 79(8):446-449.
20. Wuttge D.M., Bruzelius M., Stemme S. T-cell recognition of lipid peroxidation products breaks tolerance to self proteins. Immunology 1999, 98(2):273-279.
21. Rasheed Z., Khan M.W., Ali R. Hydroxyl radical modification of human serum albumin generated cross reactive antibodies. Autoimmunity 2006, 39(6):479-488.
22. Yu J., Heck S., Patel V., et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008, 112(4):1325-1328.
23. Stasi R., Cooper N., Del Poeta G., et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008, 112(4):1147-1150.
24. Olsson B., Ridell B., Carlsson L., et al. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 2008, 112(4):1078-1084.
25. Semple J.W. ITP three R's: regulation, routing, rituximab. Blood 2008, 112(4):927-928.
26. Brahmachari S., Pahan K. Myelin basic protein priming reduces the expression of Foxp3 in T cells via nitric oxide. J Immunol 2010, 184(4):1799-1809.
27. Brox A.G., Howson-Jan K., Fauser A.A. Treatment of idiopathic thrombocytopenic purpura with ascorbate. Br J Haematol 1988, 70(3):341-344.
28. Masugi J., Iwai M., Kimura S., et al. Combination of ascorbic acid and methylprednisolone pulse therapy in the treatment of idiopathic thrombocytopenic purpura. Intern Med 1994, 33(3):165-166.
29. Cohen H.A., Nussinovitch M., Gross S., et al. Treatment of chronic idiopathic thrombocytopenic purpura with ascorbate. Clin Pediatr (Phila) 1993, 32(5):300-302.
30. Rossetti F., Labate P., Pillon M. L-ascorbic acid for the treatment of childhood chronic idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 1992, 9(2):179-181.
31. Jubelirer S.J. Pilot study of ascorbic acid for the treatment of refractory immune thrombocytopenic purpura. Am J Hematol 1993, 43(1):44-46.
32. Amendola G., Cirillo G., Spiezie M., et al. Treatment of childhood chronic idiopathic thrombocytopenic purpura with ascorbate. Clin Pediatr (Phila 1995, 34(5):268-270.